BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Initial Data From Aastrom Biosciences, Inc. (ASTM)'s IMPACT-DCM Trial Presented At International Society for Cellular Therapy Annual Meeting by Amit N. Patel, M.D.


5/5/2009 12:36:00 PM

ANN ARBOR, Mich., May 5, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced today that Dr. Amit N. Patel, Associate Professor of Surgery at the University of Utah School of Medicine and the National Principal Investigator of the Company's U.S. Phase II IMPACT-DCM clinical trial, presented initial trial data during an oral presentation today at the International Society for Cellular Therapy (ISCT) annual meeting in San Diego, California. The clinical trial is evaluating Aastrom's Cardiac Repair Cells (CRCs) for the treatment of patients suffering from both ischemic and non-ischemic dilated cardiomyopathy (DCM), a severe form of chronic heart failure. Currently, 13 of 40 patients have been enrolled in the trial, and enrollment is on target to be completed by the end of calendar year 2009.

Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES